Adamas Pharma (ADMS) Lower on $50M Stock Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ADMS Hot Sheet
Join SI Premium – FREE
Adamas Pharma (NASDAQ: ADMS) is lower after the company filed a prospectus covering $50 million in common stock. Shares will be offered through Cowen.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bolt Biotherapeutics acquires Prana Therapies, raises $120M
- Genmab reports Phase 2 response rate data for petosemtamab in mCRC
- Vertex's povetacicept hits key endpoints in Phase 3 kidney disease trial
Create E-mail Alert Related Categories
Equity OfferingsRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
